Current Report Filing (8-k)
23 Juni 2023 - 10:02PM
Edgar (US Regulatory)
false 0001828522 --12-31 0001828522 2023-06-22 2023-06-22 0001828522 eftr:CommonStock0.0001ParValuePerShare2Member 2023-06-22 2023-06-22 0001828522 eftr:WarrantsToPurchaseCommonStock1Member 2023-06-22 2023-06-22
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported): June 22, 2023
eFFECTOR Therapeutics, Inc.
(Exact name of registrant as specified in its charter)
|
|
|
|
|
| Delaware |
|
001-39866 |
|
85-3306396 |
| (State or other jurisdiction of incorporation) |
|
(Commission File Number) |
|
(I.R.S. Employer Identification No.) |
|
|
|
|
|
| 142 North Cedros Avenue, Suite B Solana Beach, California |
|
92075 |
| (Address of principal executive offices) |
|
(Zip Code) |
(858) 925-8215
(Registrant’s telephone number, including area code)
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| ☐ |
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| ☐ |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| ☐ |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| ☐ |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
|
|
|
|
|
| Title of each class |
|
Trading Symbol(s) |
|
Name of each exchange on which registered |
| Common stock, $0.0001 par value per share |
|
EFTR |
|
Nasdaq Capital Market |
| Warrants to purchase common stock |
|
EFTRW |
|
Nasdaq Capital Market |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (Sec.230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (Sec.240.12b-2 of this chapter).
Emerging growth company ☒
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
| Item 5.03 |
Amendments to Articles of Incorporation of Bylaws; Change in Fiscal Year. |
On June 22, 2023, eFFECTOR Therapeutics, Inc. (the “Company”) held its 2023 Annual Meeting of Stockholders (the “2023 Annual Meeting”). At the 2023 Annual Meeting, as described below under Item 5.07, the stockholders of the Company approved an amendment to the Company’s Amended and Restated Certificate of Incorporation, to eliminate the personal liability of the Company’s officers for monetary damages for breach of fiduciary duty as an officer, except to the extent such an exemption from liability or limitation thereof is not permitted by Delaware General Corporation Law (the “Amendment”). The Amendment became effective upon the Company’s filing of a Certificate of Amendment to the Amended and Restated Certificate of Incorporation with the Secretary of State of Delaware on June 23, 2023 (“Certificate of Amendment”). The foregoing description of the Amendment is qualified in its entirety by reference to the full text of the Certificate of Amendment, a copy of which is attached as Exhibit 3.1 hereto and is incorporated by reference herein.
| Item 5.07 |
Submission of Matters to a Vote of Security Holders. |
The following is a brief description of each matter voted upon at the 2023 Annual Meeting and the number of votes cast for, withheld or against, the number of abstentions and the number of broker non-votes with respect to each matter, as applicable.
| |
1. |
The election of two directors to serve as Class II directors for a three-year term to expire at the 2026 Annual Meeting of Stockholders. The following two Class II directors were elected by the votes indicated: |
|
|
|
|
|
|
|
|
|
|
|
|
|
| |
|
For |
|
|
Withheld |
|
|
Broker Non-Votes |
|
| Brian M. Gallagher, Jr., Ph.D. |
|
|
22,236,484 |
|
|
|
78,863 |
|
|
|
3,910,190 |
|
| Chris Ehrlich |
|
|
22,080,109 |
|
|
|
235,238 |
|
|
|
3,910,190 |
|
| John W. Smither |
|
|
22,177,889 |
|
|
|
137,458 |
|
|
|
3,910,190 |
|
| |
2. |
The ratification of the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2023. The appointment was ratified by the votes indicated: |
|
|
|
|
|
|
|
| For |
|
Against |
|
Abstain |
|
Broker Non-Votes |
| 26,027,327 |
|
194,404 |
|
3,806 |
|
— |
| |
3. |
The approval of an amendment to the Company’s Amended and Restated Certificate of Incorporation to reflect new Delaware law provisions to permit exculpation of certain officers. The proposal was approved by the votes indicated: |
|
|
|
|
|
|
|
| For |
|
Against |
|
Abstain |
|
Broker Non-Votes |
| 22,132,333 |
|
129,561 |
|
53,453 |
|
3,910,190 |
| |
4. |
The approval of the proposal to grant the Board of Directors authority to effect a reverse stock split of the Company’s outstanding common stock by amending the Company’s Amended and Restated Certificate of Incorporation within one year and within a range of not less than one-for-five and not more than one-for-thirty. The proposal was approved by the votes indicated: |
|
|
|
|
|
|
|
| For |
|
Against |
|
Abstain |
|
Broker Non-Votes |
| 25,171,187 |
|
1,015,950 |
|
38,400 |
|
— |
| Item 9.01. |
Financial Statements and Exhibits. |
(d) Exhibits
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
|
|
|
|
|
|
|
|
|
eFFECTOR Therapeutics, Inc. |
|
|
|
| Date: June 23, 2023 |
|
By: |
|
/s/ Michael Byrnes |
|
|
|
|
Name: |
|
Michael Byrnes |
|
|
|
|
Title: |
|
Chief Financial Officer |
eFFECTOR Therapeutics (NASDAQ:EFTR)
Historical Stock Chart
Von Mai 2024 bis Jun 2024
eFFECTOR Therapeutics (NASDAQ:EFTR)
Historical Stock Chart
Von Jun 2023 bis Jun 2024
